Filing Flows

Filing Flows › Health Care › Tilray Brands (TLRY)

Tilray Brands (TLRY) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Oct 8, 2026 · Tilray Brands (TLRY) Q1 FY27 earnings results →

Q1 FY27 Revenue up 23% year over year to $257M · 16¢ of every $1 of revenue lost · operating margin -9.4%

Tilray Brands made $257M in Q1 FY27 (+23% Y/Y): Beverage Alcohol Business $101M, Distribution Business $84.3M, Cannabis Segment $56.1M. Operating margin -9.4%, net loss $40.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 8, 2026.

Revenue$257M
Year over year+23%
Operating margin-9.4%
Net earnings−$40.0M
Operating cash flow−$16.5M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $257.1M in Q1 FY27, up 23% year over year and down 9% from the previous quarter. Beverage Alcohol Business was the largest line at 39% of revenue. Beverage Alcohol Business added $45.8M year over year (up 82%), 96% of the total change. Cannabis Segment declined 13%.

Gross margin was 30.1%, up 2.7 points from Q1 FY26. Operating costs exceeded revenue by $24.1M, an operating margin of -9.4%. Operating expenses grew 83% against revenue growth of 23%. The fastest-growing cost line was Other operating costs (+581%). The quarter ended with a net loss of $40.0M, wider than the previous quarter's $37.9M loss.

Operating cash flow was −$16.5M. Non-cash charges added back $6.6M of share-based compensation. Working capital and other items added $16.9M.

Quarterly history

Tilray Brands revenue by quarterTilray Brands revenue by quarter$186MQ3 FY25$225MQ4 FY25$210MQ1 FY26$218MQ2 FY26$207MQ3 FY26$282MQ4 FY26$257MQ1 FY27
Tilray Brands net earnings by quarterTilray Brands net earnings by quarter−$794MQ3 FY25−$1.3BQ4 FY25$1.5MQ1 FY26−$43.5MQ2 FY26−$25.2MQ3 FY26−$37.9MQ4 FY26−$40.0MQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QOct 8, 2026$257M+23%-9.4%−$40.0M−$16.5M
Q4 FY2610-KJul 28, 2026$282M+26%-5.8%−$37.9M−$37.3M
Q3 FY2610-QApr 1, 2026$207M+11%-12.8%−$25.2M−$21.9M
Q2 FY2610-QJan 8, 2026$218M+3%-10.2%−$43.5M−$8.5M
Q1 FY2610-QOct 9, 2025$210M+5%1.0%$1.5M−$1.3M
Q4 FY2510-KJul 29, 2025$225M-2%-643.1%−$1.3B−$12.8M
Q3 FY2510-QApr 8, 2025$186M-1%-409.0%−$794M−$5.8M

Charts

Tilray Brands: revenue growth, year over year and quarter over quarterTilray Brands: revenue growth, year over year and quarter over quarterY/YQ/Q-1%Q3 FY25-2%+21%Q4 FY25+5%-7%Q1 FY26+3%+4%Q2 FY26+11%-5%Q3 FY26+26%+36%Q4 FY26+23%-9%Q1 FY27
Latest (Q1 FY27): Y/Y +23%, Q/Q -9%.
Tilray Brands: where the cash came from (+) and went (−), TTM to Q1 FY27Tilray Brands: where the cash came from (+) and went (−), TTM to Q1 FY27Shares issued$158MOperating cash flow−$84.3MAcquisitions−$54.4MCash drawn (+) / kept (−)$46.5MOther investing−$38.4MOther financing−$26.3MNet borrowing (+) / repaid (−)−$6.4MAsset & business sales$3.3MExchange rates$2.3M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Tilray Brands: profit against cash, quarter by quarterTilray Brands: profit against cash, quarter by quarterNet incomeOperating cash flow−$85.3M−$40.7MQ2 FY25−$794M−$5.8MQ3 FY25−$1.3B−$12.8MQ4 FY25$1.5M−$1.3MQ1 FY26−$43.5M−$8.5MQ2 FY26−$25.2M−$21.9MQ3 FY26−$37.9M−$37.3MQ4 FY26−$40.0M−$16.5MQ1 FY27
Latest (Q1 FY27): Net income −$40.0M, Operating cash flow −$16.5M.
Tilray Brands: diluted shares by fiscal year (split-adjusted)Tilray Brands: diluted shares by fiscal year (split-adjusted)539MFY21481MFY22618MFY2374MFY2489MFY25112MFY26
-79.3% since FY21: buybacks shrank the count; earlier years scaled for the 2-for-1 split before FY22.
Tilray Brands in its industry: growth against margin (22 companies, SIC 2833)Tilray Brands in its industry: growth against margin (22 companies, SIC 2833)revenue growth, year over year →↑ operating marginmedian +6%median -6%CURLFTRLVUSNAAAWHCRONCGCJUSHBTMDMRMDNAIINAGEMTEXFTLFLEEEFCHUCHYEXMEHACBDYADIANPHCCFOOTLRY (+23%, -9%)
Medicinal Chemicals & Botanical Products; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Tilray Brands

Tilray Brands, Inc., a Delaware corporation (collectively, along with its subsidiaries, the “Company”, “Tilray”, “we”, “us” and “our”) is a leading global lifestyle consumer products company, which was incorporated on January 24, 2018 and is headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and wellness, while creating memorable experiences that bring people together.

In its own words, from its 10-K, filed Jul 28, 2026.

Tilray Brands against its Medicinal Chemicals & Botanical Products peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +23% against the peers' median +7%. Operating margin: -9.4% against the peers' median 4.2%.

CompanyQuarterRevenueY/YOp. margin
TLRY Tilray BrandsQ1 FY27$257M+23%-9.4%
CURLF Curaleaf HoldingsQ3 2026$353M+11%0.8%
TRLV Trulieve CannabisQ3 2026$230M-20%18.5%
USNA Usana Health SciencesQ2 2026$223M-5%-9.0%
AAWH Ascend Wellness HoldingsQ2 2026$126M-0.9%4.2%
CRON Cronos GroupQ3 2026$83.9M+72%10.8%
CGC Canopy GrowthQ2 FY27$71.1M+20%-23.1%
JUSH Jushi HoldingsQ3 2026$70.5M+7%5.0%
BTMD bioteQ3 2026$43.3M-10%5.7%

Source: Tilray Brands 10-Q on SEC EDGAR · CIK 1731348 · Medicinal Chemicals & Botanical Products

13F: who owns TLRY and who is buying

Largest holders of TLRY (13F)Largest holders of TLRY (13F)Tidal Investments LLC$11.2MSusquehanna International Group, …$4.6MMorgan Stanley$4.5MVanguard Group$3.9MCitadel Advisors LLC$3.9MPoint72 Asset Management, L.P.$2.9MMirae Asset Global ETFS Holdings$2.9MAQR Capital Management LLC$2.3MBlackRock$2.1MUBS Group AG$2.0M
Funds' net buying of TLRY by quarter (13F)Funds' net buying of TLRY by quarter (13F)$02024-12$02025-03$2K2025-09$93.8M2025-12−$1.8M2026-03$16.4M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on TLRY

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare TLRY with

中文版：Tilray Brands（TLRY）财报

Español · Français